Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Porcine Sodium Heparin vs Heparin Sodium in Healthy Subjects
NCT05788900Phase 1Unknown
- Sponsor
- Blau Farmacêutica
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of heparin in thromboembolism (2 arms), sponsored by Blau Farmacêutica. Primary endpoints: Maximum Activity (Amax) for Anti-FXa at 12 hours, Area Under the Effect Curve from time 0 to t (ASCE0-t) for Anti-FXa at 12 hours and 3 more. Status: unknown.
02
Drugs
heparin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT05788900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788900.